Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
Crossref DOI link: https://doi.org/10.1007/s13555-023-01076-x
Published Online: 2024-01-20
Published Print: 2024-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rand, Kim http://orcid.org/0000-0001-7692-4099
Ramos-Goñi, Juan Manuel http://orcid.org/0000-0002-9568-5190
Akmaz, Bülent
Solé-Feu, Laia
Armario-Hita, José-Carlos http://orcid.org/0000-0001-6620-4725
Text and Data Mining valid from 2024-01-01
Version of Record valid from 2024-01-20
Article History
First Online: 20 January 2024